Bulk Manufacturer of Controlled Substances Application: Nanosyn, Inc., 48867-48868 [2018-21074]

Download as PDF Federal Register / Vol. 83, No. 188 / Thursday, September 27, 2018 / Notices Practice and Procedure (19 CFR part 210). By order of the Commission. Issued: September 21, 2018. Lisa Barton, Secretary to the Commission. [FR Doc. 2018–21007 Filed 9–26–18; 8:45 am] BILLING CODE 7020–02–P JOINT BOARD FOR THE ENROLLMENT OF ACTUARIES Invitation for Membership on Advisory Committee Joint Board for the Enrollment of Actuaries. ACTION: Request for applications. AGENCY: The Joint Board for the Enrollment of Actuaries (Joint Board), established under the Employee Retirement Income Security Act of 1974 (ERISA), is responsible for the enrollment of individuals who wish to perform actuarial services under ERISA. To assist in its examination duties mandated by ERISA, the Joint Board established the Advisory Committee on Actuarial Examinations (Advisory Committee) in accordance with the provisions of the Federal Advisory Committee Act (FACA). The current Advisory Committee members’ terms expire on February 28, 2019. This notice describes the Advisory Committee and invites applications from those interested in serving on the Advisory Committee for the March 1, 2019– February 28, 2021 term. DATES: Applications for membership on the Advisory Committee must be received no later than December 7, 2018. SUMMARY: You may mail or deliver applications to: Internal Revenue Service; Joint Board for the Enrollment of Actuaries; SE:RPO, Room 3422/IR, Attn: Ms. Elizabeth Van Osten; 1111 Constitution Avenue NW, Washington, DC 20224. Applications may also be sent electronically to: nhqjbea@irs.gov. See SUPPLEMENTARY INFORMATION for application requirements. FOR FURTHER INFORMATION CONTACT: Elizabeth Van Osten, Designated Federal Officer, at 202–317–3648. SUPPLEMENTARY INFORMATION: daltland on DSKBBV9HB2PROD with NOTICES ADDRESSES: 1. Background To qualify for enrollment to perform actuarial services under ERISA, an applicant must satisfy certain experience and knowledge requirements, which are set forth in the Joint Board’s regulations. An applicant VerDate Sep<11>2014 17:20 Sep 26, 2018 Jkt 244001 48867 may satisfy the knowledge requirement through the successful completion of Joint Board examinations in basic actuarial mathematics and methodology and in actuarial mathematics and methodology relating to pension plans qualifying under ERISA. The Joint Board, the Society of Actuaries, and the American Society of Pension Professionals & Actuaries jointly offer examinations acceptable to the Joint Board for enrollment purposes and which are acceptable to the other two actuarial organizations as part of their respective examination programs members affiliated with any one actuarial organization or employed with any one firm. Membership normally will be limited to actuaries currently enrolled by the Joint Board. However, individuals having academic or other special qualifications of particular value for the Advisory Committee’s work will also be considered for membership. Federallyregistered lobbyists and individuals affiliated with Joint Board enrollment examination preparation courses are not eligible to serve on the Advisory Committee. 2. Scope of Advisory Committee Duties The Advisory Committee plays an integral role in the examination program by assisting the Joint Board in offering examinations that enable examination candidates to demonstrate the knowledge necessary to qualify for enrollment. The Advisory Committee’s duties, which are strictly advisory, include (1) recommending topics for inclusion on the Joint Board examinations, (2) reviewing and drafting examination questions, (3) recommending examinations, (4) reviewing examination results and recommending passing scores, and (5) providing other recommendations and advice relative to the examinations, as requested by the Joint Board. 5. Member Designation 3. Member Terms and Responsibilities Members are appointed for a 2-year term. The upcoming term will begin on March 1, 2019, and end on February 28, 2021. Members may seek reappointment for additional consecutive terms. Members are expected to attend approximately 4 meetings each calendar year and are reimbursed for travel expenses in accordance with applicable government regulations. In general, members are expected to devote 125 to 175 hours, including meeting time, to the work of the Advisory Committee over the course of a year. 4. Member Selection The Joint Board seeks to appoint an Advisory Committee that is fairly balanced in terms of points of view represented and functions to be performed. Every effort is made to ensure that most points of view extant in the enrolled actuary profession are represented on the Advisory Committee. To that end, the Joint Board seeks to appoint several members from each of the main practice areas of the enrolled actuary profession, including small employer plans, large employer plans, and multiemployer plans. In addition, to ensure diversity of points of view, the Joint Board limits the number of PO 00000 Frm 00075 Fmt 4703 Sfmt 4703 Advisory Committee members are appointed as Special Government Employees (SGEs). As such, members are subject to certain ethical standards applicable to SGEs. Upon appointment, each member will be required to provide written confirmation that he/ she does not have a financial interest in a Joint Board examination preparation course. In addition, each member will be required to attend annual ethics training. 6. Application Requirements To receive consideration, an individual interested in serving on the Advisory Committee must submit (1) a signed, cover letter expressing interest in serving on the Advisory Committee and describing his/her professional qualifications, and (2) a resume and/or curriculum vitae. Applications may be submitted by regular mail, overnight and express delivery services, and email. In all cases, the cover letter must contain an original signature. Applications must be received by December 7, 2018. Dated: September 19, 2018. Thomas V. Curtin, Jr., Executive Director, Joint Board for the Enrollment of Actuaries. [FR Doc. 2018–21001 Filed 9–26–18; 8:45 am] BILLING CODE 4830–01–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Bulk Manufacturer of Controlled Substances Application: Nanosyn, Inc. ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the DATES: E:\FR\FM\27SEN1.SGM 27SEN1 48868 Federal Register / Vol. 83, No. 188 / Thursday, September 27, 2018 / Notices issuance of the proposed registration on or before November 26, 2018. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.33(a), this is notice that on July 10, 2018, Nanosyn, Inc., 3331–B Industrial Drive, Santa Rosa, California 95403– 2062 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances: SUPPLEMENTARY INFORMATION: Controlled substance Drug code Oxymorphone ....... Fentanyl ................ 9652 9801 or objections to the issuance of the proposed registration on or before November 26, 2018. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW 8701 Morrissette Drive, Springfield, Virginia 22152. The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.33(a), this is notice that on August 27, 2018, Absolute Standards, Inc., 44 Rossotto Drive, Hamden, CT 06514 applied to be registered as a bulk manufacturer for the basic classes of controlled substances: SUPPLEMENTARY INFORMATION: Schedule II II Controlled substance Drug code Pentobarbital ........ The company is a contract manufacturer. At the request of the company’s customers, it manufactures derivatives of controlled substance in bulk form. Dated: September 19, 2018. John J. Martin, Assistant Administrator. 2270 Schedule II The company plans to bulk manufacture the listed controlled substance for distribution to customers. Dated: September 21, 2018. John J. Martin, Assistant Administrator. [FR Doc. 2018–21075 Filed 9–26–18; 8:45 am] BILLING CODE 4410–09–P [FR Doc. 2018–21074 Filed 9–26–18; 8:45 am] BILLING CODE 4410–09–P daltland on DSKBBV9HB2PROD with NOTICES DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Federal Bureau of Investigation Drug Enforcement Administration [OMB Number: 1110–0068] [Docket No. DEA–392] Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of a Currently Approved Collection: Records Modification Form (FD–1115) Bulk Manufacturer of Controlled Substances Application: Absolute Standards, Inc. ACTION: Notice of application. Registered bulk manufacturers of the affected basic class, and applicants therefore, may file written comments on DATES: VerDate Sep<11>2014 17:20 Sep 26, 2018 Jkt 244001 Criminal Justice Information Services Division, Federal Bureau of Investigation, Department of Justice. ACTION: 60-Day notice. AGENCY: PO 00000 Frm 00076 Fmt 4703 Sfmt 4703 The Department of Justice (DOJ), Federal Bureau of Investigation (FBI), Criminal Justice Information Services (CJIS) Division, will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. DATES: Comments are encouraged and will be accepted for 60 days until November 26, 2018. FOR FURTHER INFORMATION CONTACT: If you have additional comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Gerry Lynn Brovey, Supervisory Information Liaison Specialist, FBI, CJIS, Resources Management Section, Administrative Unit, Module C–2, 1000 Custer Hollow Road, Clarksburg, West Virginia 26306 (facsimile: 304–625– 5093) or email glbrovey@fbi.gov. Written comments and/or suggestions can also be sent to the Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Officer, Washington, DC 20503. Additionally, comments may be submitted via email to OIRA_submission@omb.eop.gov. SUPPLEMENTARY INFORMATION: This process is conducted in accordance with 5 CFR 1320.10. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Evaluate whether and if so how the quality, utility, and clarity of the information to be collected can be enhanced; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms SUMMARY: E:\FR\FM\27SEN1.SGM 27SEN1

Agencies

[Federal Register Volume 83, Number 188 (Thursday, September 27, 2018)]
[Notices]
[Pages 48867-48868]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-21074]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Bulk Manufacturer of Controlled Substances Application: Nanosyn, 
Inc.

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the

[[Page 48868]]

issuance of the proposed registration on or before November 26, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, dispensers, importers, and exporters of 
controlled substances (other than final orders in connection with 
suspension, denial, or revocation of registration) has been redelegated 
to the Assistant Administrator of the DEA Diversion Control Division 
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R.
    In accordance with 21 CFR 1301.33(a), this is notice that on July 
10, 2018, Nanosyn, Inc., 3331-B Industrial Drive, Santa Rosa, 
California 95403-2062 applied to be registered as a bulk manufacturer 
of the following basic classes of controlled substances:

------------------------------------------------------------------------
         Controlled substance           Drug code         Schedule
------------------------------------------------------------------------
Oxymorphone..........................         9652  II
Fentanyl.............................         9801  II
------------------------------------------------------------------------

    The company is a contract manufacturer. At the request of the 
company's customers, it manufactures derivatives of controlled 
substance in bulk form.

    Dated: September 19, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-21074 Filed 9-26-18; 8:45 am]
 BILLING CODE 4410-09-P